The Alzheimer’s Association clinical practice guideline for the diagnostic evaluation, testing, counseling, and disclosure of suspected Alzheimer’s disease and related disorders (DETeCD‐ADRD): Validated clinical assessment instruments

by Clinical Neuropsychologist | Monday, December 23, 2024 | Dementia

Abstract US clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to Alzheimer’s Disease (AD) or AD and related dementias (ADRD) are decades old and aimed at specialists. This evidence-based guideline was developed to empower...

Psychotropic medication usage in sporadic versus genetic behavioral‐variant frontotemporal dementia

by Clinical Neuropsychologist | Monday, December 23, 2024 | Dementia

Abstract INTRODUCTION Psychotropic medication (PM) use in behavioral-variant frontotemporal dementia (bvFTD) is higher than in other dementias. However, no information exists on whether PM use differs between sporadic and genetic bvFTD. METHODS We analyzed data from...

Association of APOE alleles and polygenic profiles comprising APOE‐TOMM40‐APOC1 variants with Alzheimer’s disease neuroimaging markers

by Clinical Neuropsychologist | Monday, December 23, 2024 | Dementia

Abstract INTRODUCTION TOMM40 and APOC1 variants can modulate the APOE-ε4-related Alzheimer’s disease (AD) risk by up to fourfold. We aim to investigate whether the genetic modulation of ε4-related AD risk is reflected in brain morphology. METHODS We tested...

Integrating rare pathogenic variant prioritization with gene‐based association analysis to identify novel genes and relevant multimodal traits for Alzheimer’s disease

by Clinical Neuropsychologist | Monday, December 23, 2024 | Dementia

Abstract INTRODUCTION Increasing evidence has highlighted rare variants in Alzheimer’s disease (AD). However, insufficient sample sizes, especially in underrepresented ethnic groups, hinder their investigation. Additionally, their impact on endophenotypes...

Identification of circulating risk biomarkers for cognitive decline in a large community‐based population in Chongqing China

by Clinical Neuropsychologist | Monday, December 23, 2024 | Dementia

Abstract INTRODUCTION This study aims to investigate the relationship between blood-based pathologies and established risk factors for cognitive decline in the community-based population of Chongqing, a region with significant aging. METHODS A total of 26,554...

Plasma Aβ42/Aβ40 is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer’s disease spectrum

by Clinical Neuropsychologist | Monday, December 23, 2024 | Dementia

Abstract INTRODUCTION The availability of amyloid beta (Aβ) targeting therapies for Alzheimer’s disease (AD) is increasing the demand for scalable biomarkers that are sensitive to early cerebral Aβ accumulation. METHODS We evaluated fully-automated Lumipulse...